Companies /Healthcare

CRISPR Therapeutics AG

NASDAQ: CRSP Biotechnology
$59.37
â–² $0.14 (+0.24%) today
Markets closed · 1:53am ET

Q1 2026 Earnings

Reported May 4, 2026, 4:41pm ET · SEC source
$-1.28
Miss −3.68%
EPS · est. $-1.23
$1.5M
Miss −65.73%
Revenue · est. $4.3M
−2.9%
Trailing market
CRSP vs S&P since report
1 quarter
Consecutive EPS beats

Market Reaction

% change · around the report
−6%−3%0May 4May 5report 4:41pm ETearnings+1.0%−2.5%
−6%−3%0May 4May 5earnings+1.0%−2.5%
CRSP −2.5%S&P 500 +1.0%
−6%−3%0May 4May 5report 4:41pm ETearnings+1.9%−2.5%
−6%−3%0May 4May 5earnings+1.9%−2.5%
CRSP −2.5%NASDAQ +1.9%
−4%0+4%May 4May 12report 4:41pm ETearnings+2.8%−0.1%
−4%0+4%May 4May 12earnings+2.8%−0.1%
CRSP −0.1%S&P 500 +2.8%
−4%0+4%May 4May 12report 4:41pm ETearnings+5.1%−0.1%
−4%0+4%May 4May 12earnings+5.1%−0.1%
CRSP −0.1%NASDAQ +5.1%
−2.24%
Day of report
+5.15%
Next session
+0.86%
One week
−1.03%
30 days

S&P 500 over the same 30 days: +1.90%.

Did CRSP Beat Earnings? Q1 2026 Results

CRISPR Therapeutics delivered a disappointing first quarter for fiscal 2026, missing on both the top and bottom lines as revenue of $1.46 million fell 65.73% short of the $4.25 million consensus estimate, despite rising 68.5% year over year, while a loss of $1.28 per share edged past the $1.23 consensus estimate by 3.68%. The primary culprit behind the revenue shortfall was the modest nature of CRISPR's own recognized revenue, which remains largely limited to collaboration and grant income, even as partner Vertex reported $43.00 million in CASGEVY sales for the quarter, with CRISPR capturing its 40% profit share through a separate collaboration expense structure. Net loss narrowed to $122.93 million from $136.00 million a year ago, aided by reduced R&D and G&A spending. With more than 500 patients globally initiating treatment and Vertex pursuing pediatric label expansion for CASGEVY in children ages 5 to 11, management described the company as entering a second phase, with six pipeline programs across cardiovascular, autoimmune, and oncology indications expected to generate data over the next 12 to 18 months.

Key Takeaways
  • CASGEVY generated $43 million in Q1 2026 revenue with over 500 patients initiating treatment globally
  • Reduced R&D and G&A expenses due to lower employee-related costs
  • Decreased collaboration expense driven by increased share of CASGEVY revenue
  • Strengthened cash position from $585.4 million convertible notes issuance

“The first quarter reflected continued execution across CRISPR Therapeutics' platform. We expanded zugo-cel into new autoimmune indications and advanced multiple in vivo liver-directed programs toward the clinic, while CASGEVY continued its momentum. With a strengthened balance sheet and multiple upcoming milestones, we believe 2026 will be a defining year for CRISPR Therapeutics.”

CRISPR Therapeutics CEO, on the earnings call

Forward Guidance & Outlook

CRISPR Therapeutics expects 2026 to be a defining year. Key milestones include: CTX310 clinical update in H2 2026; CTX460 clinical trial initiation in mid-2026; CTX340 clinical trial initiation in H1 2026; CTX321 Lp(a) program update in 2026; CTX611 Phase 2 update in H2 2026; zugo-cel autoimmune program updates in H2 2026; zugo-cel immuno-oncology updates in H2 2026; Vertex submission for CASGEVY pediatric approval (ages 5-11) under accelerated FDA review; and continued CASGEVY commercial expansion with German pricing agreement implementation. The company has a strengthened balance sheet with $2.4 billion in cash, cash equivalents, and marketable securities following a convertible notes issuance.

CRSP YoY Financials

Q1 2026 vs Q1 2025 · SEC filings Q1 2025 Q1 2026
$-120,000,000$-80,000,000$-40,000,000$0$865,025$1.5MRevenue$-116,033,853$-130,248,000Operating Income$-112,153,088$-122,931,000Net Income
$-120,000,000$-80,000,000$-40,000,000$0RevenueOperating IncomeNet Income

CRSP Revenue by Segment

CASGEVY$43.0M

Figures from SEC filings and company reports. Not investment advice.